BCRX Q4 2025 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$407M+209.1% YoY

Gross Profit

$397M97.6% margin

Operating Income

$260M64.0% margin

Net Income

$246M60.5% margin

EPS (Diluted)

$1.12

QoQ Revenue Growth

+155.1%

Cash Flow

Operating Cash Flow

$276M

Free Cash Flow

$275M

Stock-Based Comp.

$73M

Balance Sheet

Total Assets

$514M

Total Liabilities

$633M

Stockholders' Equity

-$119M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$407M	$132M	+209.1%
Gross Profit	$397M	$125M	+216.3%
Operating Income	$260M	-$5M	+5876.1%
Net Income	$246M	-$27M	+1017.5%

Revenue Segments

License

$708,000100%